Moderna IncMRNA has exercised its option to license Autolus Therapeutics plc’sAUTL proprietary binders against an undisclosed immuno-oncology target for the development and commercialization of mRNA therapeutics.
This follows an original agreement with Moderna announced in August 2021, granting Moderna an exclusive option to license Autolus’ proprietary binders for up to four immuno-oncology targets for incorporation in certain mRNA therapeutics.
On exercise of the option, Autolus has received an option exercise payment and is eligible to receive development and commercial milestone payments for each product successfully commercialized.
In addition, Autolus would receive royalties on net sales of all products commercialized under the agreement.
Price Action: AUTL shares are up 8.89% at $3.24 on the last check Wednesday.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
